Leadless Pacemaker Messaging for Non-Vascular ICD Arrhythmia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional implantable cardioverter defibrillators (ICDs) with transvenous leads and intracardiac electrodes face complications such as lead system malfunction, infection, and require specialized implantation, while non-vascular ICDs using extracardiac electrodes are susceptible to under-sensing and noise interference, leading to inappropriate therapy delivery.
Innovation Solution
A system comprising a leadless pacemaker (LP) and a non-vascular implantable cardioverter defibrillator (NV-ICD) with bidirectional communication, where the LP senses near-field electrograms and paces the heart, while the NV-ICD senses far-field electrograms, allowing for improved arrhythmia discrimination and therapy delivery through implant-to-implant messaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If transvenous leads and intracardiac electrodes are used in conventional ICDs, then sensing precision and arrhythmia detection accuracy are improved, but device complexity, surgical difficulty, and risk of lead-related complications increase
Solution Approach 1:
The patent extracts the sensing function from the complex transvenous lead system and relocates it to a separate implantable loop recorder (ILR) device. This allows the ICD to use simpler extracardiac electrodes while the ILR provides precise intracardiac electrogram sensing through dedicated intracardiac electrodes, resolving the contradiction between sensing precision and device complexity
Solution Approach 2:
The ILR acts as an intermediary device that bridges the gap between the simple NV-ICD system and the need for precise intracardiac sensing. The ILR receives intracardiac electrograms from its own electrodes and transmits this high-fidelity sensing data to the NV-ICD, enabling accurate arrhythmia detection without requiring the ICD itself to have complex lead systems
2Reliability
If transvenous lead systems are used, then effective arrhythmia treatment is achieved, but long-term reliability deteriorates due to lead malfunction, fracture, and infection
Solution Approach 1:
The patent separates the vulnerable transvenous lead system from the ICD by using an ILR with its own dedicated intracardiac electrodes. The ILR's electrodes are positioned independently and do not share the same vulnerable transvenous pathway, reducing the risk of lead-related complications affecting the ICD's long-term reliability
Solution Approach 2:
The system is segmented into two independent devices: the NV-ICD for therapy delivery and the ILR for precise sensing. This segmentation allows each device to be optimized independently, with the ILR handling the risky intracardiac electrode function while the NV-ICD maintains simple extracardiac electrodes, improving overall system reliability
3Device complexity
If non-vascular ICDs with extracardiac electrodes are used, then device complexity and surgical difficulty are reduced, but sensing accuracy deteriorates due to under-sensing and noise interference
Solution Approach 1:
The ILR serves as an intermediary that provides high-fidelity intracardiac electrogram sensing to the NV-ICD. The ILR's intracardiac electrodes capture precise cardiac electrical signals free from the noise and under-sensing problems that plague extracardiac electrodes, and this clean signal is transmitted to the NV-ICD for accurate arrhythmia detection
Solution Approach 2:
The patent merges the sensing capabilities of two different electrode systems: the NV-ICD's simple extracardiac electrodes for basic monitoring and the ILR's precise intracardiac electrodes for accurate arrhythmia detection. This combination allows the system to maintain low complexity while achieving high sensing accuracy through data fusion from both electrode types
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Implantable systems (100) that detect arrhythmic episodes and perform arrhythmia discrimination are described. Such a system (100) includes a leadless pacemaker (LP) (102a, 102b) that senses a near-field electrogram (NF-EGM), and a non-vascular implantable cardioverter defibrillator (NV-ICD) (106) that senses a far-field electrogram (FF-EGM). The LP (102a, 102b) determines cardiac activity information based on the NF-EGM and optionally also based on paced cardiac events caused by the LP (102a, 102b). The LP (102a, 102b) monitors for specific pacemaker condition(s), sends i2i message(s) including the cardiac activity information to the NV-ICD (106) when at least one of the specific pacemaker condition(s) is detected by the LP (102a, 102b), and does not send i2i message(s) including the cardiac activity information to the NV-ICD (106) when the LP (102a, 102b) detects none of the specific pacemaker condition(s). After the NV-ICD (106) receives the i2i message(s) transmitted by the LP (102a, 102b), the NV-ICD (106) can detect an arrhythmic episode and/or perform arrhythmia discrimination based on the cardiac activity information included therein.